Trebananib was associated with more adverse event-related treatment discontinuations than was placebo ( @ -LSB- @ % -RSB- patients vs @ -LSB- @ % -RSB- , respectively ) and higher incidences of oedema ( @ -LSB- @ % -RSB- patients had any-grade oedema in the trebananib group vs @ -LSB- @ % -RSB- patients in the placebo group ) .